|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000101134 |
Summary for DOK5 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000101134 | Gene symbol | DOK5 |
| Gene name | docking protein 5 | |
| HGNC | 16173 | |
| Entrez ID | 55816 | |
| Gene type | protein_coding | |
| Synonyms | DOK5|dJ805C22.1 | |
| UniProtAcc | Q9P104 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for DOK5 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| DOK5 | 2.13e+02 | -1.40e+00 | 3.94e-01 | -3.55e+00 | 3.82e-04 | 5.63e-03 | BRCA |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| DOK5 | 2.38e+02 | -1.18e+00 | 2.83e-01 | -4.15e+00 | 3.29e-05 | 1.31e-04 | THCA |
| DOK5 | 1.90e+02 | -2.15e+00 | 5.48e-01 | -3.93e+00 | 8.65e-05 | 2.87e-04 | KICH |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| DOK5 | 9.32e+02 | 1.37e+00 | 4.62e-01 | 2.96e+00 | 3.10e-03 | 1.27e-02 | KIRP |
Top |
Sex-biased somatic mutation for DOK5 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for DOK5 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg23359394 | chr20:54475501 | CGI:chr20:54475194-54476454 | promoter | 2.61e-01 | 4.93e-01 | -2.52e+00 | 1.17e-02 | 2.83e-02 | -2.31e-01 |
| BRCA | cg20107395 | chr20:54475795 | CGI:chr20:54475194-54476454 | UTR,promoter,exon,gene body | 2.80e-01 | 4.75e-01 | -1.96e+00 | 4.95e-02 | 4.97e-02 | -1.95e-01 |
| BRCA | cg11822659 | chr20:54476242 | CGI:chr20:54475194-54476454 | promoter,gene body | 2.80e-01 | 4.36e-01 | -2.28e+00 | 2.25e-02 | 3.66e-02 | -1.56e-01 |
| BRCA | cg14606116 | chr20:54476279 | CGI:chr20:54475194-54476454 | promoter,gene body | 2.21e-01 | 3.25e-01 | -2.37e+00 | 1.78e-02 | 3.35e-02 | -1.05e-01 |
| BRCA | cg09177519 | chr20:54476445 | CGI:chr20:54475194-54476454 | promoter,gene body | 2.68e-01 | 4.06e-01 | -2.56e+00 | 1.06e-02 | 2.73e-02 | -1.38e-01 |
| BRCA | cg05101674 | chr20:54476613 | CGI:chr20:54475194-54476454 | promoter,gene body | 3.40e-01 | 5.36e-01 | -2.13e+00 | 3.36e-02 | 4.29e-02 | -1.96e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg09177519 | chr20:54476445 | CGI:chr20:54475194-54476454 | promoter,gene body | 2.49e-01 | 1.43e-01 | 3.13e+00 | 1.77e-03 | 3.13e-03 | 1.05e-01 |
| HNSC | cg00741836 | chr20:54475694 | CGI:chr20:54475194-54476454 | UTR,promoter,exon,gene body | 2.53e-01 | 3.74e-02 | 4.10e+00 | 4.10e-05 | 1.23e-04 | 2.15e-01 |
| HNSC | cg09260441 | chr20:54475200 | CGI:chr20:54475194-54476454 | promoter | 2.43e-01 | 1.17e-01 | 3.15e+00 | 1.60e-03 | 2.71e-03 | 1.27e-01 |
| LUSC | cg05101674 | chr20:54476613 | CGI:chr20:54475194-54476454 | promoter,gene body | 3.45e-01 | 1.06e-01 | 2.82e+00 | 4.78e-03 | 7.89e-03 | 2.39e-01 |
| COAD | cg09177519 | chr20:54476445 | CGI:chr20:54475194-54476454 | promoter,gene body | 3.76e-01 | 2.60e-01 | 3.45e+00 | 5.56e-04 | 1.39e-03 | 1.16e-01 |
| BLCA | cg23359394 | chr20:54475501 | CGI:chr20:54475194-54476454 | promoter | 1.37e-01 | 2.33e-02 | 3.56e+00 | 3.66e-04 | 1.04e-03 | 1.14e-01 |
| BLCA | cg11822659 | chr20:54476242 | CGI:chr20:54475194-54476454 | promoter,gene body | 2.45e-01 | 1.05e-01 | 2.29e+00 | 2.19e-02 | 2.62e-02 | 1.40e-01 |
| BLCA | cg09177519 | chr20:54476445 | CGI:chr20:54475194-54476454 | promoter,gene body | 2.46e-01 | 1.36e-01 | 2.53e+00 | 1.15e-02 | 1.58e-02 | 1.10e-01 |
| KIRP | cg27212232 | chr20:54475061 | CGI:chr20:54475194-54476454 | promoter | 3.97e-01 | 2.94e-01 | 3.63e+00 | 2.79e-04 | 6.18e-04 | 1.03e-01 |
| CHOL | cg23359394 | chr20:54475501 | CGI:chr20:54475194-54476454 | promoter | 2.19e-01 | 3.67e-02 | 2.21e+00 | 2.70e-02 | 3.50e-02 | 1.83e-01 |
| CHOL | cg27212232 | chr20:54475061 | CGI:chr20:54475194-54476454 | promoter | 3.86e-01 | 1.86e-01 | 2.95e+00 | 3.19e-03 | 1.32e-02 | 2.00e-01 |
| CHOL | cg09260441 | chr20:54475200 | CGI:chr20:54475194-54476454 | promoter | 3.16e-01 | 9.26e-02 | 2.73e+00 | 6.38e-03 | 1.82e-02 | 2.24e-01 |
| CHOL | cg11822659 | chr20:54476242 | CGI:chr20:54475194-54476454 | promoter,gene body | 2.96e-01 | 8.34e-02 | 2.29e+00 | 2.23e-02 | 3.24e-02 | 2.13e-01 |
| CHOL | cg14606116 | chr20:54476279 | CGI:chr20:54475194-54476454 | promoter,gene body | 2.51e-01 | 1.19e-01 | 2.14e+00 | 3.25e-02 | 3.87e-02 | 1.32e-01 |
| CHOL | cg09177519 | chr20:54476445 | CGI:chr20:54475194-54476454 | promoter,gene body | 3.38e-01 | 1.44e-01 | 1.99e+00 | 4.65e-02 | 4.65e-02 | 1.94e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg23359394 | chr20:54475501 | CGI:chr20:54475194-54476454 | promoter | 2.61e-01 | 2.84e-02 | 1.09e+01 | 1.58e-27 | 1.73e-26 | 2.33e-01 |
| BRCA | cg00741836 | chr20:54475694 | CGI:chr20:54475194-54476454 | UTR,promoter,exon,gene body | 2.68e-01 | 3.34e-02 | 9.62e+00 | 6.36e-22 | 4.06e-21 | 2.35e-01 |
| BRCA | cg27341128 | chr20:54475720 | CGI:chr20:54475194-54476454 | UTR,promoter,exon,gene body | 2.61e-01 | 6.69e-02 | 1.10e+01 | 4.90e-28 | 5.67e-27 | 1.94e-01 |
| BRCA | cg20107395 | chr20:54475795 | CGI:chr20:54475194-54476454 | UTR,promoter,exon,gene body | 2.80e-01 | 3.01e-02 | 8.98e+00 | 2.80e-19 | 1.42e-18 | 2.50e-01 |
| BRCA | cg09260441 | chr20:54475200 | CGI:chr20:54475194-54476454 | promoter | 2.06e-01 | 9.79e-02 | 6.93e+00 | 4.25e-12 | 1.24e-11 | 1.08e-01 |
| BRCA | cg00055557 | chr20:54475935 | CGI:chr20:54475194-54476454 | UTR,promoter,exon,gene body | 2.75e-01 | 1.06e-01 | 1.12e+01 | 5.52e-29 | 7.13e-28 | 1.69e-01 |
| BRCA | cg11822659 | chr20:54476242 | CGI:chr20:54475194-54476454 | promoter,gene body | 2.80e-01 | 9.40e-02 | 9.50e+00 | 2.20e-21 | 1.34e-20 | 1.86e-01 |
| BRCA | cg09177519 | chr20:54476445 | CGI:chr20:54475194-54476454 | promoter,gene body | 2.68e-01 | 1.22e-01 | 9.53e+00 | 1.59e-21 | 9.78e-21 | 1.46e-01 |
| BRCA | cg05101674 | chr20:54476613 | CGI:chr20:54475194-54476454 | promoter,gene body | 3.40e-01 | 1.05e-01 | 8.33e+00 | 8.12e-17 | 3.40e-16 | 2.34e-01 |
| LIHC | cg23359394 | chr20:54475501 | CGI:chr20:54475194-54476454 | promoter | 1.43e-01 | 2.71e-02 | 2.58e+00 | 9.75e-03 | 1.36e-02 | 1.16e-01 |
| LIHC | cg00741836 | chr20:54475694 | CGI:chr20:54475194-54476454 | UTR,promoter,exon,gene body | 2.15e-01 | 3.32e-02 | 2.62e+00 | 8.74e-03 | 1.25e-02 | 1.82e-01 |
| LIHC | cg27341128 | chr20:54475720 | CGI:chr20:54475194-54476454 | UTR,promoter,exon,gene body | 2.44e-01 | 9.57e-02 | 2.36e+00 | 1.83e-02 | 2.25e-02 | 1.48e-01 |
| LIHC | cg20107395 | chr20:54475795 | CGI:chr20:54475194-54476454 | UTR,promoter,exon,gene body | 1.30e-01 | 2.24e-02 | 2.42e+00 | 1.57e-02 | 1.99e-02 | 1.08e-01 |
Top |
Exon skipping events with PSI in TCGA for DOK5 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for DOK5 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for DOK5 |
| TFs related to DOK5. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| DLBC | EMX1 | DOK5 | 3.47e+00 | 7.97e-03 | 4.43e+00 | 9.85e-01 | Female-biased |
| DLBC | EMX2 | DOK5 | 3.28e+00 | 6.70e-03 | 4.28e+00 | 9.84e-01 | Female-biased |
| DLBC | EN1 | DOK5 | 3.56e+00 | 8.47e-03 | 4.50e+00 | 9.85e-01 | Female-biased |
| DLBC | NKX3-1 | DOK5 | 2.81e+00 | 2.23e-03 | 4.11e+00 | 9.85e-01 | Female-biased |
| DLBC | POU6F2 | DOK5 | 3.28e+00 | 7.62e-03 | 4.25e+00 | 9.82e-01 | Female-biased |
| DOK5 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for DOK5 |
| RBPs related to ES in DOK5. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| MESO | KHDRBS3 | exon_skip_353001 | 7.68e+00 | 8.82e-03 | 8.04e+00 | 9.83e-01 | Female-biased |
| MESO | ZC3H10 | exon_skip_353002 | 9.44e+00 | 9.91e-01 | 9.04e+00 | 6.31e-03 | Male-biased |
| DOK5 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs10485799 | chr20:55670853:C:T | - | 0.0789977613479775 | 0.0194943645195561 | KIRC | Female-baised eQTL |
| rs114834273 | chr20:55670988:C:T | - | 0.0789977613479775 | 0.0194943645195561 | KIRC | Female-baised eQTL |
| rs6097354 | chr20:53309296:G:A | - | 0.0671533053987452 | 0.0263268154725946 | LUAD | Female-baised eQTL |
| rs1371066 | chr20:60481251:A:G | - | 0.0520306479188138 | 0.0364915222030106 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs73165761 | chr20:56656687:C:A | - | 0.171970240546334 | 0.00146604613070624 | GBM | Male-baised eQTL |
| rs1293422 | chr20:53130383:G:C | - | 0.110617817692185 | 0.0111489965589548 | SARC | Male-baised eQTL |
| rs1293417 | chr20:53142382:A:C | - | 0.125627543422463 | 0.0185430975404045 | SARC | Male-baised eQTL |
| rs1293414 | chr20:53144123:A:G | - | 0.125627543422463 | 0.0185430975404045 | SARC | Male-baised eQTL |
| rs1293420 | chr20:53139496:C:T | - | 0.11982112498082 | 0.026240059052494 | SARC | Male-baised eQTL |
| rs1293407 | chr20:53159776:T:C | - | 0.116062094773805 | 0.0419450492491631 | SARC | Male-baised eQTL |
| rs1293406 | chr20:53160007:T:G | - | 0.116062094773805 | 0.0419450492491631 | SARC | Male-baised eQTL |
| rs3730164 | chr20:58895462:G:A | - | 0.0395662986798213 | 0.00941837945944721 | KIRC | Male-baised eQTL |
| rs6094477 | chr20:46792863:T:C | - | 0.0422229471384172 | 0.0121215287933548 | KIRC | Male-baised eQTL |
| rs6092704 | chr20:58893423:A:C | - | 0.0367235120468541 | 0.0271795550272156 | KIRC | Male-baised eQTL |
| rs6092437 | chr20:57166199:G:A | - | 0.0913310437751013 | 0.00357820955941264 | LUAD | Male-baised eQTL |
| rs76122264 | chr20:57736648:G:A | - | 0.0886159351362383 | 0.0165743471351441 | LUAD | Male-baised eQTL |
| rs6025327 | chr20:57039836:C:T | - | 0.0758012931787415 | 0.029383935953658 | LUAD | Male-baised eQTL |
| rs404727 | chr20:56890378:A:G | - | -0.0500420908212511 | 0.0326217308970198 | LUAD | Male-baised eQTL |
| rs715434 | chr20:52662016:A:G | - | 0.0737974775477808 | 0.0341598834296767 | LUAD | Male-baised eQTL |
| rs7274515 | chr20:52658140:G:A | - | 0.0729264848076524 | 0.0386548572810513 | LUAD | Male-baised eQTL |
| rs1568724 | chr20:52671326:A:T | - | 0.0701945962184193 | 0.0477415790993986 | LUAD | Male-baised eQTL |
| rs17807252 | chr20:52669900:A:G | - | 0.0702445695680228 | 0.0478047816886797 | LUAD | Male-baised eQTL |
| rs17807318 | chr20:52678553:T:G | - | 0.0706027883229117 | 0.048858382028152 | LUAD | Male-baised eQTL |
| rs4811382 | chr20:52680565:T:C | - | 0.0706027883229117 | 0.048858382028152 | LUAD | Male-baised eQTL |
| rs6022042 | chr20:52681496:C:T | - | 0.0706027883229117 | 0.048858382028152 | LUAD | Male-baised eQTL |
| rs8124840 | chr20:57590494:G:T | - | 0.0446998526335271 | 0.0498596757331556 | LUAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000101134 |
| CpG Site: cg09177519 | |
| Position to Gene: gene,promoter | |
| Male Effect: - | |
| Female Effect: -0.0534526116038901 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg09177519 | chr20:54476445 | gene,promoter | -0.0534526116038901 | 3.55446109263576e-07 | -0.3749268296895319 | 6.219695990995619e-10 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of DOK5 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000101134 | DOK5 | C0005586 | Bipolar Disorder | 1 | PSYGENET |
